Palovarotene

From WikiMD's Food, Medicine & Wellness Encyclopedia

Palovarotene is a retinoic acid receptor gamma (RAR-γ) agonist that is currently under investigation for its potential therapeutic applications. It was originally developed by Clementia Pharmaceuticals, which was later acquired by Ipsen in 2019. Palovarotene is primarily being studied for its potential use in the treatment of Fibrodysplasia Ossificans Progressiva (FOP) and Multiple Osteochondromas (MO), both of which are rare and debilitating skeletal disorders.

History[edit | edit source]

Palovarotene was first developed by Clementia Pharmaceuticals, a company that was later acquired by Ipsen in 2019. The acquisition was primarily driven by Ipsen's interest in the potential of Palovarotene as a treatment for rare diseases.

Mechanism of Action[edit | edit source]

As a RAR-γ agonist, Palovarotene works by binding to the retinoic acid receptor gamma, a type of nuclear receptor that is involved in cell differentiation and proliferation. By activating this receptor, Palovarotene can potentially inhibit the process of heterotopic ossification, which is a hallmark of conditions like FOP and MO.

Clinical Trials[edit | edit source]

Palovarotene has undergone several clinical trials to evaluate its safety and efficacy. These trials have primarily focused on its potential use in the treatment of FOP and MO. While the results have been promising, further research is needed to fully understand the potential of Palovarotene as a therapeutic agent.

Potential Therapeutic Applications[edit | edit source]

The primary therapeutic applications of Palovarotene are in the treatment of FOP and MO. Both of these conditions are characterized by abnormal bone growth, and current treatment options are limited. By inhibiting the process of heterotopic ossification, Palovarotene could potentially offer a new treatment option for patients with these conditions.

See Also[edit | edit source]

References[edit | edit source]

‎ ‎


Wiki.png

Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Search WikiMD


Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD

WikiMD is not a substitute for professional medical advice. See full disclaimer.

Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.

Contributors: Admin, Prab R. Tumpati, MD